|
Mar 20
|
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
|
|
Mar 19
|
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
|
|
Mar 6
|
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
|
|
Jan 9
|
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
|
|
Jan 9
|
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
|
|
Dec 4
|
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
|
|
Nov 30
|
Precision BioSciences to Present at Hep-DART 2023
|
|
Nov 28
|
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 9
|
Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
|
|
Nov 7
|
Precision BioSciences Inc (DTIL) Reports Q3 2023 Financial Results
|
|
Nov 7
|
Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
|
|
Aug 6
|
Analysts Just Published A Bright New Outlook For Precision BioSciences, Inc.'s (NASDAQ:DTIL)
|
|
Aug 4
|
Precision BioSciences (DTIL) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 4
|
Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update
|
|
May 31
|
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
|
|
May 25
|
Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023
|
|
May 9
|
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 9
|
Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update
|
|
May 8
|
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
|